Market Overview

Morgan Stanley Reiterates Overweight Rating on Gilead Sciences on Phase III Data

Share:
Related GILD
Gilead Sciences Get European Commission Grant For Marketing Authorization Of Its Single Tablet Regimen Odefsey
As Buybacks Soar, Buyback ETF Tries To Get Its Groove Back
Rating Last Week's Editors' Picks: A Purely Quantitative Perspective (Seeking Alpha)

In a report published Monday, Morgan Stanley reiterated its Overweight rating on Gilead Sciences (NASDAQ: GILD).

Morgan Stanley noted, “Additional Phase III data for 7977/sofosbuvir are as expected and continue to support a best in class profile and a multi-billion dollar opportunity for Gilead with a likely launch in 1H14. Despite investor concern around FISSION, a similar 67% SVR rate to PEG-riba for an all-oral 12-week regimen looks solid, but GT2/3 remains a more minor part of the long term opportunity (~30% of US patients). For NEUTRINO in GT1 with PEG-riba, an 89% SVR rate in GT1 looks good and use in this setting could be an early source of launch upside ahead of the all-oral GT1 approval in 2015. Discontinuation rates of 1% in FISSION and 2% in NEUTRINO continue to support 7977's strong safety profile. The program is on track for a mid-2013 filing with full Phase III data for both likely at EASL in April.”

Gilead Sciences closed on Friday at $40.56.

Latest Ratings for GILD

DateFirmActionFromTo
Jun 2016Gabelli & CoInitiates Coverage onBuy
May 2016Morgan StanleyMaintainsEqual-weight
Apr 2016CitigroupMaintainsBuy

View More Analyst Ratings for GILD
View the Latest Analyst Ratings

Posted-In: Morgan StanleyAnalyst Color Reiteration Analyst Ratings

 

Related Articles (GILD)

View Comments and Join the Discussion!